항균 치료제 시장(2026-2030년)

The global antimicrobial therapeutics market is forecasted to grow by USD 65671.3 mn during 2025-2030, accelerating at a CAGR of 6.1% during the forecast period. The report on the global antimicrobial therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating global prevalence of antimicrobial resistance and multi-drug resistant pathogens, accelerated regulatory approvals and strategic pipeline enhancements, integration of ai and precision medicine platforms in drug discovery.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global antimicrobial therapeutics market is segmented as below:

By Application

• Antiviral
• Antibacterial
• Antifungal
• Antiparasitic

By End-User

• Pharmacies
• Hospitals and clinics
• Research and academic institutes

By Route Of Administration

• Oral
• Intravenous
• Topical
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift toward narrow-spectrum and pathogen-targeted therapeutics as one of the prime reasons driving the global antimicrobial therapeutics market growth during the next few years. Also, integration of rapid diagnostics with precision antimicrobial protocols and exploration of alternative modalities beyond conventional small-molecule antibiotics will lead to sizable demand in the market.

The report on the global antimicrobial therapeutics market covers the following areas:

• Global antimicrobial therapeutics market sizing
• Global antimicrobial therapeutics market forecast
• Global antimicrobial therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global antimicrobial therapeutics market vendors that include AbbVie Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Basilea Pharmaceutica Ltd., Bayer AG, Cipla Inc., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Innoviva Inc., Johnson and Johnson, Melinta Therapeutics LLC, Merck and Co. Inc., Paratek Pharmaceuticals Inc., Pfizer Inc., Sandoz Group AG, SHIONOGI Co. Ltd., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc., Wockhardt Ltd.. Also, the global antimicrobial therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Antimicrobial Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Antimicrobial Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.3 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.4 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global antimicrobial therapeutics market
• 6.2 Impact of geopolitical conflicts on global antimicrobial therapeutics market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Antiviral - Market size and forecast 2025-2030
• 8.4 Antibacterial - Market size and forecast 2025-2030
• 8.5 Antifungal - Market size and forecast 2025-2030
• 8.6 Antiparasitic - Market size and forecast 2025-2030
• 8.7 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Pharmacies - Market size and forecast 2025-2030
• 9.4 Hospitals and clinics - Market size and forecast 2025-2030
• 9.5 Research and academic institutes - Market size and forecast 2025-2030
• 9.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Route of Administration

• 10.1 Market segments
• 10.2 Comparison by Route of Administration
• 10.3 Oral - Market size and forecast 2025-2030
• 10.4 Intravenous - Market size and forecast 2025-2030
• 10.5 Topical - Market size and forecast 2025-2030
• 10.6 Others - Market size and forecast 2025-2030
• 10.7 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 Turkey - Market size and forecast 2025-2030
  • 12.6.4 UAE - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Escalating global prevalence of antimicrobial resistance and multi-drug resistant pathogens
  • Accelerated regulatory approvals and strategic pipeline enhancements
  • Integration of AI and precision medicine platforms in drug discovery
• 13.2 Market challenges
  • Economic disincentives and commercial viability deficits
  • Complex regulatory pathways and stringent approval standards
  • Vulnerabilities within global active pharmaceutical ingredient supply chains
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Shift toward narrow-spectrum and pathogen-targeted therapeutics
  • Integration of rapid diagnostics with precision antimicrobial protocols
  • Exploration of alternative modalities beyond conventional small-molecule antibiotics

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Astellas Pharma Inc.
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key news
  • Astellas Pharma Inc. - Key offerings
  • SWOT
• 15.6 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
• 15.7 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.8 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.9 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.11 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Business segments
  • Gilead Sciences Inc. - Key news
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Segment focus
  • SWOT
• 15.12 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.13 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 15.14 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.16 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Business segments
  • Sandoz Group AG - Key news
  • Sandoz Group AG - Key offerings
  • Sandoz Group AG - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations